Pharmacokinetics and bioavailability of tranexamic acid
Tranexamic acid 1 g was given intravenously to three healthy volunteers. Plasma concentrations decayed in three monoexponential phases. Most elimination took place during the first eight hours, giving an apparent elimination half-life of approximately two hours. Plasma clearance ranged between 110-1...
Saved in:
| Published in: | European journal of clinical pharmacology Vol. 20; no. 1; pp. 65 - 72 |
|---|---|
| Main Authors: | , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Germany
01-01-1981
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Tranexamic acid 1 g was given intravenously to three healthy volunteers. Plasma concentrations decayed in three monoexponential phases. Most elimination took place during the first eight hours, giving an apparent elimination half-life of approximately two hours. Plasma clearance ranged between 110-116 ml/min. The urinary recovery of tranexamic acid exceeded 95% of the dose. Ten healthy volunteers were given tranexamic acid 2 g orally on an empty stomach, and together with a meal. Food had no influence on the absorption of tranexamic acid, as judged by comparison of the peak plasma concentration, the time required to reach the peak, the AUC from zero to six hours, and the urinary excretion data. The oral bioavailability of tranexamic acid, calculated from 24 h urinary excretion after oral and intravenous administration, was 34% of the dose. |
|---|---|
| AbstractList | Tranexamic acid 1 g was given intravenously to three healthy volunteers. Plasma concentrations decayed in three monoexponential phases. Most elimination took place during the first eight hours, giving an apparent elimination half-life of approximately two hours. Plasma clearance ranged between 110-116 ml/min. The urinary recovery of tranexamic acid exceeded 95% of the dose. Ten healthy volunteers were given tranexamic acid 2 g orally on an empty stomach, and together with a meal. Food had no influence on the absorption of tranexamic acid, as judged by comparison of the peak plasma concentration, the time required to reach the peak, the AUC from zero to six hours, and the urinary excretion data. The oral bioavailability of tranexamic acid, calculated from 24 h urinary excretion after oral and intravenous administration, was 34% of the dose. |
| Author | Pilbrant, A Vessman, J Schannong, M |
| Author_xml | – sequence: 1 givenname: A surname: Pilbrant fullname: Pilbrant, A – sequence: 2 givenname: M surname: Schannong fullname: Schannong, M – sequence: 3 givenname: J surname: Vessman fullname: Vessman, J |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/7308275$$D View this record in MEDLINE/PubMed |
| BookMark | eNpFkEtLAzEYRYNUalvduBdm5UIYzZfnZKnFqlDQha6HTB4YnZnUZCrtv7fSoqu7ORwuZ4pGfewdQueArwFjeXO3wJhzJoQ6QhNglJSAGYzQBGMKpVASn6Bpzh8YA1eYjtFYUlwRySdIvrzr1GkTP0PvhmByoXtbNCHqbx1a3YQ2DNsi-mJIuncb3QVTaBPsKTr2us3u7LAz9La4f50_lsvnh6f57bI0lNChlGBtpRUH4p1gxCpaMecJr6zVSnoBzgpJoAEDlgvvFa88t42uvGWcU0Vn6HLvXaX4tXZ5qLuQjWvb3Zu4zrWkkgkGsAOv9qBJMefkfL1KodNpWwOufyvV_5V28MXBum46Z__QQxb6A6d6Yu4 |
| CitedBy_id | crossref_primary_10_3389_fphar_2021_639694 crossref_primary_10_1016_j_arth_2016_02_081 crossref_primary_10_1046_j_1365_2516_2002_00678_x crossref_primary_10_1016_j_jtcvs_2006_01_064 crossref_primary_10_1093_asj_sjad177 crossref_primary_10_2106_JBJS_16_00188 crossref_primary_10_5811_westjem_2018_8_39336 crossref_primary_10_1097_BSD_0000000000000999 crossref_primary_10_1007_s00264_018_3846_6 crossref_primary_10_1111_cbdd_12224 crossref_primary_10_1016_j_jse_2016_02_002 crossref_primary_10_1016_S0022_5223_95_70118_4 crossref_primary_10_1016_j_jaci_2011_11_025 crossref_primary_10_1111_anae_16058 crossref_primary_10_1177_10760296211002277 crossref_primary_10_3109_00365528709089756 crossref_primary_10_3390_molecules27072271 crossref_primary_10_52628_88_2_8383 crossref_primary_10_1007_s00264_018_3925_8 crossref_primary_10_2165_11209070_000000000_00000 crossref_primary_10_1186_s12978_020_0887_2 crossref_primary_10_1016_j_ijsu_2019_03_011 crossref_primary_10_1111_tme_12780 crossref_primary_10_1016_j_ijsu_2017_08_009 crossref_primary_10_1186_s12884_018_1855_5 crossref_primary_10_1563_AAID_JOI_D_13_00158 crossref_primary_10_1016_j_jse_2021_04_031 crossref_primary_10_3390_jcm9113684 crossref_primary_10_1016_j_jos_2020_10_011 crossref_primary_10_1093_asj_sjaa198 crossref_primary_10_1016_j_ocl_2021_03_004 crossref_primary_10_1021_acs_molpharmaceut_7b00286 crossref_primary_10_1007_s00586_017_5230_4 crossref_primary_10_1007_s40262_013_0033_1 crossref_primary_10_1097_BSD_0000000000000808 crossref_primary_10_1517_14656566_2010_508071 crossref_primary_10_1046_j_1365_2516_1998_00147_x crossref_primary_10_1097_SLA_0000000000003793 crossref_primary_10_1097_PRS_0000000000005620 crossref_primary_10_1002_j_1552_4604_1987_tb05605_x crossref_primary_10_1111_coa_14059 crossref_primary_10_1016_j_arth_2018_04_024 crossref_primary_10_1053_j_jvca_2010_08_012 crossref_primary_10_1597_14_263 crossref_primary_10_1097_ALN_0000000000001787 crossref_primary_10_1097_TA_0000000000001779 crossref_primary_10_1007_s12285_020_00261_7 crossref_primary_10_1186_s12891_018_1996_8 crossref_primary_10_1007_s00266_024_03951_0 crossref_primary_10_1080_03007995_2019_1708533 crossref_primary_10_1155_2020_2514207 crossref_primary_10_5301_hipint_5000550 crossref_primary_10_1111_bcpt_12847 crossref_primary_10_1213_ane_0b013e3181679555 crossref_primary_10_1111_trf_14477 crossref_primary_10_1586_17474108_2013_841452 crossref_primary_10_1177_1060028017735859 crossref_primary_10_1016_j_nwh_2021_12_003 crossref_primary_10_1111_fcp_12474 crossref_primary_10_1053_j_sart_2021_12_006 crossref_primary_10_1089_fpsam_2020_0061 crossref_primary_10_1016_j_bpa_2022_08_004 crossref_primary_10_1111_bcp_13460 crossref_primary_10_1002_jps_1031 crossref_primary_10_1016_j_ajem_2016_10_054 crossref_primary_10_3171_2016_8_SPINE16528 crossref_primary_10_1016_j_thromres_2014_11_012 crossref_primary_10_1055_s_0041_1740585 crossref_primary_10_1097_AOG_0000000000003750 crossref_primary_10_5792_ksrr_16_074 crossref_primary_10_1016_j_amjoto_2022_103590 crossref_primary_10_1001_jamaoto_2018_1381 crossref_primary_10_1007_s10822_013_9666_2 crossref_primary_10_1111_coa_12645 crossref_primary_10_1016_j_talanta_2020_121945 crossref_primary_10_1016_j_bpobgyn_2015_11_016 crossref_primary_10_1111_trf_15030 crossref_primary_10_1186_s12948_020_00131_8 crossref_primary_10_1097_ALN_0b013e3182a443e8 crossref_primary_10_1186_s13018_021_02616_x crossref_primary_10_1186_s42836_020_00027_7 crossref_primary_10_1002_j_1552_4604_1992_tb03787_x crossref_primary_10_1186_s13018_022_03095_4 crossref_primary_10_1080_14767058_2019_1571576 crossref_primary_10_1007_s00266_024_03992_5 crossref_primary_10_1016_j_ijom_2017_10_007 crossref_primary_10_1097_00000539_200105000_00010 crossref_primary_10_1111_j_1600_0412_2012_01361_x crossref_primary_10_1186_s13063_018_2626_3 crossref_primary_10_1016_j_arth_2016_06_058 crossref_primary_10_1007_BF03217790 crossref_primary_10_3390_pharmaceutics14102255 crossref_primary_10_1097_TA_0b013e318232ea1e crossref_primary_10_1016_j_jpba_2017_04_024 crossref_primary_10_1302_0301_620X_100B8_BJJ_2017_1598_R1 crossref_primary_10_1302_2046_3758_68_BJR_2017_0005_R1 crossref_primary_10_1007_s11239_018_1705_3 crossref_primary_10_1002_bio_4463 crossref_primary_10_1016_j_thromres_2018_02_007 crossref_primary_10_12688_wellcomeopenres_16884_1 crossref_primary_10_1007_s43465_023_00875_w crossref_primary_10_1213_ANE_0000000000002724 crossref_primary_10_1016_j_ejcts_2010_12_030 crossref_primary_10_1097_MBC_0000000000000789 crossref_primary_10_1002_elps_200410282 crossref_primary_10_1302_0301_620X_95B11_31055 crossref_primary_10_1177_1076029618783258 crossref_primary_10_52628_87_4_14 crossref_primary_10_1097_CORR_0000000000000378 crossref_primary_10_1016_j_ejps_2021_105893 crossref_primary_10_1016_j_jchromb_2004_03_013 crossref_primary_10_1186_s13256_023_03768_6 crossref_primary_10_1002_bjs5_50192 crossref_primary_10_1111_j_1365_2044_2012_07266_x crossref_primary_10_1002__SICI_1098_2752_1996_17_5_278__AID_MICR8_3_0_CO_2_F crossref_primary_10_1177_0310057X18811977 crossref_primary_10_1186_s12959_023_00540_0 crossref_primary_10_1345_aph_1R025 crossref_primary_10_1111_jocd_13301 crossref_primary_10_1016_j_thromres_2018_10_006 crossref_primary_10_1097_MD_0000000000022999 crossref_primary_10_3390_nu14061248 crossref_primary_10_1111_os_13407 crossref_primary_10_1136_bmjopen_2024_084847 crossref_primary_10_1016_j_wneu_2018_09_115 crossref_primary_10_1111_jth_14316 crossref_primary_10_4137_CMWH_S6314 crossref_primary_10_1001_jamasurg_2021_0884 crossref_primary_10_1111_jvp_13407 crossref_primary_10_1186_s12884_023_05728_w crossref_primary_10_1007_s40262_021_01043_9 crossref_primary_10_1016_j_jss_2016_09_023 crossref_primary_10_1111_jmwh_13101 crossref_primary_10_1016_j_medcli_2023_06_035 crossref_primary_10_1097_BRS_0000000000002954 crossref_primary_10_1016_j_ejps_2020_105486 crossref_primary_10_1097_GCO_0000000000000470 crossref_primary_10_3390_pharmaceutics14030578 crossref_primary_10_1016_j_joms_2008_08_015 crossref_primary_10_1053_j_jvca_2007_12_016 crossref_primary_10_1111_aogs_14567 crossref_primary_10_1002_ijgo_14201 crossref_primary_10_3928_01477447_20230224_04 crossref_primary_10_1097_MJT_0b013e318205427a crossref_primary_10_1016_j_jaip_2016_12_014 crossref_primary_10_1093_asj_sjz232 crossref_primary_10_1186_s13063_017_2421_6 crossref_primary_10_1002_micr_1920120504 crossref_primary_10_1016_j_spinee_2020_10_011 crossref_primary_10_1016_j_wneu_2019_01_040 crossref_primary_10_1016_j_thromres_2018_09_054 crossref_primary_10_1016_j_watres_2022_118305 crossref_primary_10_1016_j_knee_2015_01_003 crossref_primary_10_1016_S0378_4347_00_84573_9 crossref_primary_10_1080_14767058_2018_1500544 crossref_primary_10_1213_ANE_0000000000006039 crossref_primary_10_1097_MBC_0000000000000980 crossref_primary_10_1007_s12630_019_01393_w crossref_primary_10_1111_aogs_12798 crossref_primary_10_1016_j_jcms_2014_03_003 crossref_primary_10_1097_TA_0000000000001861 crossref_primary_10_1186_s13063_019_3561_7 crossref_primary_10_1016_j_bja_2022_11_003 crossref_primary_10_1016_j_ijpharm_2024_124219 crossref_primary_10_34239_ajops_v5n1_277 crossref_primary_10_1016_j_thromres_2018_04_026 crossref_primary_10_1177_1060028019876077 crossref_primary_10_1016_j_arth_2016_10_003 crossref_primary_10_1016_j_ajogmf_2022_100573 crossref_primary_10_1124_jpet_113_210880 crossref_primary_10_1007_s11838_019_00096_8 crossref_primary_10_1111_j_1471_0528_1995_tb10881_x crossref_primary_10_3109_00016349409023453 crossref_primary_10_1002_app_49785 crossref_primary_10_1097_SCS_0000000000002273 crossref_primary_10_1097_SCS_0000000000002835 crossref_primary_10_1007_s00586_013_2836_z crossref_primary_10_1016_j_knee_2017_07_004 crossref_primary_10_1097_BRS_0b013e3181fb3a42 |
| Cites_doi | 10.1007/BF01061504 10.1111/j.1600-0404.1972.tb07561.x 10.1007/BF00558210 10.1007/BF01066219 10.1016/S0140-6736(73)90525-4 10.3109/00016346709158657 10.1002/jps.2600650534 10.1021/ac50011a012 10.3109/00365596909135401 10.1111/j.1749-6632.1968.tb20322.x 10.1111/j.1600-0404.1973.tb01288.x 10.1002/jps.2600600616 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
| DOI | 10.1007/BF00554669 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE |
| Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1432-1041 |
| EndPage | 72 |
| ExternalDocumentID | 10_1007_BF00554669 7308275 |
| Genre | Journal Article |
| GroupedDBID | --- -4W -56 -5G -BR -EM -Y2 -~C .86 .GJ .VR 04C 06C 06D 0R~ 0VY 199 1N0 1SB 2.D 203 28- 29G 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3O- 3SX 3V. 4.4 406 408 409 40D 40E 476 53G 5QI 5RE 5VS 67N 67Z 6NX 6PF 78A 7RV 7X7 88E 8AO 8FI 8FJ 8FW 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAEOY AAHNG AAIAL AAJBT AAJKR AANXM AANZL AAQLM AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAYIU AAYOK AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTHY ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFO ACGFS ACHSB ACHVE ACHXU ACIHN ACIPQ ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACREN ACZOJ ADBBV ADHHG ADHIR ADINQ ADJJI ADKNI ADKPE ADOJX ADRFC ADTPH ADURQ ADYFF ADYOE ADYPR ADZKW AEAQA AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFDYV AFEXP AFFNX AFGCZ AFKRA AFLOW AFQWF AFRAH AFWTZ AFYQB AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMTXH AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BKEYQ BMSDO BPHCQ BVXVI CAG CCPQU CGR COF CS3 CSCUP CUY CVF DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS ECM ECT EIF EIHBH EIOEI EJD EMB EMOBN EN4 EPAXT ESBYG EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M4Y MA- MK0 N2Q N9A NAPCQ NB0 NDZJH NPM NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S3A S3B SAP SBL SBY SCLPG SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZN T13 T16 TSG TSK TSV TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK6 WK8 WOW Y6R YLTOR Z45 Z7U Z7V Z7W Z81 Z82 Z83 Z87 Z8O Z8P Z8Q Z8U Z8V Z8W Z91 ZGI ZMTXR ZOVNA ZXP ~EX ~KM AAYXX CITATION 7X8 |
| ID | FETCH-LOGICAL-c323t-71dd8a9512fe642d9384ef258dda97f61ed6721b1c1d56ff958f5dba8fd455393 |
| ISSN | 0031-6970 |
| IngestDate | Fri Oct 25 08:22:07 EDT 2024 Thu Nov 21 23:54:13 EST 2024 Wed Oct 16 00:48:52 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c323t-71dd8a9512fe642d9384ef258dda97f61ed6721b1c1d56ff958f5dba8fd455393 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 7308275 |
| PQID | 73746411 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_73746411 crossref_primary_10_1007_BF00554669 pubmed_primary_7308275 |
| PublicationCentury | 1900 |
| PublicationDate | 1981-01-01 |
| PublicationDateYYYYMMDD | 1981-01-01 |
| PublicationDate_xml | – month: 01 year: 1981 text: 1981-01-01 day: 01 |
| PublicationDecade | 1980 |
| PublicationPlace | Germany |
| PublicationPlace_xml | – name: Germany |
| PublicationTitle | European journal of clinical pharmacology |
| PublicationTitleAlternate | Eur J Clin Pharmacol |
| PublicationYear | 1981 |
| References | L Andersson (BF00554669_CR1) 1968; 146 L Nilsson (BF00554669_CR8) 1967; 46 W Westlake (BF00554669_CR13) 1971; 60 S Niazi (BF00554669_CR7) 1976; 65 D Tovi (BF00554669_CR9) 1972; 48 O Eriksson (BF00554669_CR4) 1974; 7 CM Metzler (BF00554669_CR6) 1974 D Tovi (BF00554669_CR10) 1973; 49 J Vessman (BF00554669_CR11) 1977; 49 PO Hedlund (BF00554669_CR5) 1969; 3 L Widlund (BF00554669_CR14) 1979 F Cormack (BF00554669_CR3) 1973; 1 JG Wagner (BF00554669_CR12) 1977; 5 HG Boxenbaum (BF00554669_CR2) 1974; 2 |
| References_xml | – volume: 2 start-page: 123 year: 1974 ident: BF00554669_CR2 publication-title: J Pharmacokinet Biopharm doi: 10.1007/BF01061504 contributor: fullname: HG Boxenbaum – volume: 48 start-page: 393 year: 1972 ident: BF00554669_CR9 publication-title: Acta Neurol Scand doi: 10.1111/j.1600-0404.1972.tb07561.x contributor: fullname: D Tovi – volume: 7 start-page: 375 year: 1974 ident: BF00554669_CR4 publication-title: Eur J Clin Pharmacol doi: 10.1007/BF00558210 contributor: fullname: O Eriksson – volume: 5 start-page: 161 year: 1977 ident: BF00554669_CR12 publication-title: J Pharmacokinet Biopharm doi: 10.1007/BF01066219 contributor: fullname: JG Wagner – volume: 1 start-page: 1207 year: 1973 ident: BF00554669_CR3 publication-title: Lancet doi: 10.1016/S0140-6736(73)90525-4 contributor: fullname: F Cormack – volume: 46 start-page: 572 year: 1967 ident: BF00554669_CR8 publication-title: Acta Obstet Gynecol Scand doi: 10.3109/00016346709158657 contributor: fullname: L Nilsson – volume: 65 start-page: 750 year: 1976 ident: BF00554669_CR7 publication-title: J Pharm Sci doi: 10.1002/jps.2600650534 contributor: fullname: S Niazi – volume: 49 start-page: 369 year: 1977 ident: BF00554669_CR11 publication-title: Anal Chem doi: 10.1021/ac50011a012 contributor: fullname: J Vessman – volume: 3 start-page: 177 year: 1969 ident: BF00554669_CR5 publication-title: Scand J Urol Nephrol doi: 10.3109/00365596909135401 contributor: fullname: PO Hedlund – volume-title: The disposition of tranexamic acid (AMCA) in different animal species and in man after oral dosage year: 1979 ident: BF00554669_CR14 contributor: fullname: L Widlund – volume: 146 start-page: 642 year: 1968 ident: BF00554669_CR1 publication-title: Ann NY Acad Sci doi: 10.1111/j.1749-6632.1968.tb20322.x contributor: fullname: L Andersson – volume-title: A users manual for NONLIN and associated programs. Research Biostatics year: 1974 ident: BF00554669_CR6 contributor: fullname: CM Metzler – volume: 49 start-page: 163 year: 1973 ident: BF00554669_CR10 publication-title: Acta Neurol Scand doi: 10.1111/j.1600-0404.1973.tb01288.x contributor: fullname: D Tovi – volume: 60 start-page: 882 year: 1971 ident: BF00554669_CR13 publication-title: J Pharm Sci doi: 10.1002/jps.2600600616 contributor: fullname: W Westlake |
| SSID | ssj0015903 |
| Score | 1.4978336 |
| Snippet | Tranexamic acid 1 g was given intravenously to three healthy volunteers. Plasma concentrations decayed in three monoexponential phases. Most elimination took... |
| SourceID | proquest crossref pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 65 |
| SubjectTerms | Administration, Oral Biological Availability Cyclohexanecarboxylic Acids - metabolism Humans Injections, Intravenous Kinetics Male Tranexamic Acid - metabolism |
| Title | Pharmacokinetics and bioavailability of tranexamic acid |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/7308275 https://search.proquest.com/docview/73746411 |
| Volume | 20 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1La9wwEBZNcuml9BW6fQpacmkMK0uy5GMfu6QlbBfqlNyMnmRp2A3d3dL--44i2YoTSttDL8IILOz5xGhmNPMNQq8sWN1GKl84zVXBmPGFFqUujDacK869qkJx8tFnMTuV7ydsklvJ5bn_ijTMAdahcvYf0O4XhQl4BsxhBNRh_Cvc54mL-iuYjz0Fs16s1He1OI-k3JeX6hs4pNyP0I3-tTKLQbvOQYQ-Wat9BeVF5rruo_HzxTk43YnBIF_tnKnlMmX89vGdL4EHNAZdP-aIA6kluRJxSFqUkqKqY8OPTouW4xu7JarE2AoiHa6xTc8NtT3uktHHIWku9m4ZcmPPPrXTk-PjtpmcNjtorwS1Alptb_ph9nbe3xrxepxIluP3Delo09pDA-Q3XsWlddHcRXeSW4DfRDzvoVtueR8dJCx_HuIml8mtD_EBnl9B4QES10HHADq-BjpeeZxBxwH0h-hkOmneHRWpI0ZhaEk3hSDWSgVGcekdOI62ppI5X3JpraqFr4izFbj0mhhieeV9zaXnVivpLeOc1nQf7QLw7hHCNSPgalPludPMlExSraWjIU2XeG3YCL3sxNReROKTtqO4zsIcoRedBFvQS-GyCf5jtV23ggpWMUJGaD8Ktl9FBIYkwR__8dUn6Hbefk_R7ubb1j1DO2u7fZ6Q_wX9ImBu |
| link.rule.ids | 315,782,786,27933,27934 |
| linkProvider | Springer Nature |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacokinetics+and+bioavailability+of+tranexamic+acid&rft.jtitle=European+journal+of+clinical+pharmacology&rft.au=Pilbrant%2C+A&rft.au=Schannong%2C+M&rft.au=Vessman%2C+J&rft.date=1981-01-01&rft.issn=0031-6970&rft.volume=20&rft.issue=1&rft.spage=65&rft.epage=72&rft_id=info:doi/10.1007%2FBF00554669&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0031-6970&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0031-6970&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0031-6970&client=summon |